- Home
- CRMD
CRMD
CorMedix Inc.
as of 12-03-2025 3:44pm EST
Cormedix Inc is a biopharmaceutical company focused on developing and commercializing therapeutic products for life-threatening diseases and conditions. The Company's focus is on the commercialization of its product, DefenCath, in the United States (U.S.) and other key markets. The group currently operates in a single segment, Drug Product, located in a single geographic location, the United States.
| Founded: | 2006 | Country: | United States |
| Employees: | N/A | City: | BERKELEY HEIGHTS |
| Market Cap: | 876.7M | IPO Year: | 2010 |
| Target Price: | $17.43 | AVG Volume (30 days): | 3.0M |
| Analyst Decision: | Strong Buy | Number of Analysts: | 7 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | 2.25 | EPS Growth: | N/A |
| 52 Week Low/High: | $5.60 - $17.43 | Next Earning Date: | 11-12-2025 |
| Revenue: | $214,303,672 | Revenue Growth: | 1647.67% |
| Revenue Growth (this year): | 565.64% | Revenue Growth (next year): | 46.09% |
AI-Powered CRMD Daily Prediction
Machine learning model trained on 25+ technical indicators
AI Recommendation
Disclaimer: This prediction is generated by an AI model and should not be considered as financial advice. Always conduct your own research and consult with financial professionals before making investment decisions.
Stock Insider Trading Activity of CorMedix Inc. (CRMD)
Director
Avg Cost/Share
$11.42
Shares
30,000
Total Value
$342,600.00
Owned After
48,473
SEC Form 4
Director
Avg Cost/Share
$11.02
Shares
25,000
Total Value
$275,500.00
Owned After
201,034
SEC Form 4
Director
Avg Cost/Share
$13.13
Shares
10,000
Total Value
$131,300.00
Owned After
40,250
SEC Form 4
Chief Operating Officer
Avg Cost/Share
$13.08
Shares
41,121
Total Value
$537,862.68
Owned After
176,990
SEC Form 4
Chief Legal Officer
Avg Cost/Share
$13.12
Shares
50,000
Total Value
$670,264.00
Owned After
180,418
Chief Operating Officer
Avg Cost/Share
$13.51
Shares
12,876
Total Value
$173,954.76
Owned After
176,990
SEC Form 4
| Insider | Ticker | Relationship | Date | Transaction | Avg Cost | Shares | Total Value | Owned After | SEC Forms |
|---|---|---|---|---|---|---|---|---|---|
| Dillione Janet | CRMD | Director | Nov 14, 2025 | Sell | $11.42 | 30,000 | $342,600.00 | 48,473 | |
| Kaplan Myron | CRMD | Director | Oct 23, 2025 | Buy | $11.02 | 25,000 | $275,500.00 | 201,034 | |
| DUNTON ALAN W | CRMD | Director | Sep 12, 2025 | Sell | $13.13 | 10,000 | $131,300.00 | 40,250 | |
| Masson-Hurlburt Elizabeth | CRMD | Chief Operating Officer | Sep 11, 2025 | Sell | $13.08 | 41,121 | $537,862.68 | 176,990 | |
| Zelnick Kaufman Beth | CRMD | Chief Legal Officer | Sep 9, 2025 | Sell | $13.12 | 50,000 | $670,264.00 | 180,418 | |
| Masson-Hurlburt Elizabeth | CRMD | Chief Operating Officer | Sep 9, 2025 | Sell | $13.51 | 12,876 | $173,954.76 | 176,990 |
Compare CRMD vs Leading Stocks
See how CRMD stacks up against similar companies in the market
Head-to-Head Comparisons
Share on Social Networks:
Tools & Resources
Enhance your trading experience with our free tools
Disclaimer
The information presented on this page, "CRMD CorMedix Inc. - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.